TRV GP V’s Maze Therapeutics MAZE Stock Holding History

TRV GP V’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.4M	Hold	950,800	–	–	5.69%	3
2026 Q1	$28.4M	Hold	950,800	–	–	7.08%	3
2025 Q4	$39.4M	Hold	950,800	–	–	9.18%	3
2025 Q3	$24.7M	Hold	950,800	–	–	6.97%	3
2025 Q2	$11.7M	Hold	950,800	–	–	7.04%	3
2025 Q1	$10.5M	Buy	+950,800	New	+$11.4M	8.37%	3

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

TRV GP V's MAZE Position: Q2 2026 in Review

TRV GP V held its Maze Therapeutics (MAZE) position steady in Q2 2026 at 950,800 shares worth $28.4M. The position accounts for 5.69% of the portfolio, ranked #3.

TRV GP V first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $39.4M in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

TRV GP V held 950,800 shares of Maze Therapeutics worth $28.4M as of Q2 2026.
TRV GP V left its Maze Therapeutics share count unchanged in Q2 2026.
Maze Therapeutics made up 5.69% of TRV GP V's portfolio in Q2 2026, its #3 holding.
TRV GP V first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
TRV GP V's Maze Therapeutics position peaked at $39.4M in Q4 2025.
162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on TRV GP V's 13F filing for Q2 2026, filed 10 Aug 2026.